| Identification | Back Directory | [Name]
Propanoic acid, 2,2-dimethyl-, 1,1'-[[(1-hydroxy-2-oxo-3-piperidinyl)phosphinylidene]bis(oxymethylene)] ester | [CAS]
2004714-34-3 | [Synonyms]
POMHEX
Propanoic acid, 2,2-dimethyl-, 1,1'-[[(1-hydroxy-2-oxo-3-piperidinyl)phosphinylidene]bis(oxymethylene)] ester | [Molecular Formula]
C17H30NO9P | [MDL Number]
MFCD34179500 | [MOL File]
2004714-34-3.mol | [Molecular Weight]
423.4 |
| Chemical Properties | Back Directory | [Boiling point ]
528.2±60.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (236.18 mM; Need ultrasonic) | [form ]
Solid | [pka]
8.70±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
POMHEX, a racemic mixture and a cell-permeable pivaloyloxymethyl (POM) proagent of HEX, is a potent, ENO2-specific inhibitor of enolase. POMHEX exhibits low-nanomolar potency against ENO1-deleted cells in vitro and is capable of eradicating ENO1-deleted xenografted tumours in vivo. POMHEX is a potent glycolysis inhibitor[1]. | [in vivo]
POMHEX (i.v., ip) injections are consistently tolerated without haemolytic anaemia at doses of up to 10 mg per kg (body weight) per day. POMHEX (i.v., 35 mg/kg) results in lethargy that prompted veterinarians to perform euthanasia[1].
?
POMHEX is rapidly hydrolysed to HemiPOMHEX in mouse plasma ex vivo, with a half-life of approximately 30 s, the half-life in human blood ex vivo was about 9min[1].
| [storage]
Store at -20°C | [References]
[1] Yu-Hsi Lin, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 Nov 23. DOI:10.1038/s42255-020-00313-3 |
|
|